Thread: FINA and ANTi E's
10-29-2002, 12:38 PM #1
FINA and ANTi E's
10-29-2002, 12:41 PM #2Member
- Join Date
- Dec 2001
No you should get some bromo to have on hand. I'd have nolv on hand too.
10-29-2002, 12:56 PM #3
10-29-2002, 03:49 PM #4
I did a search on dostinex, looks like a viagra alternative.
10-29-2002, 05:12 PM #5
Here's a study on the advantages of Dostinex over Bromocriptine, Where did you see this data of it being a viagra alternative, dizzle?
Until Dostinex became available in the U.S., the only other dopamine agonist approved for the treatment of prolactinomas and/or hyperprolactinemia was bromocriptine. However, Dostinex has proved to have a number of advantages over bromocriptine:
Lower incidence of side effects
Twice weekly dosing versus 2-3 times daily for bromocriptine
Generally more effective, especially in those in which bromocriptine was ineffective
Disadvantages of Dostinex over Bromocriptine
Dostinex is twice as expensive as bromocriptine
Dostinex is not available in all countries
Dostinex is not approved for use during pregnancy, and its effects on pregnancy are unknown at this time
The side effects associated with Dostinex usually disappear or are reduced after a few doses. However, if you miss a dose, you may experience some of the original side effects for a short time. The most common side effects of Dostinex are:
Clinical Trial Results
Webster et al., 1994. Comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 31: 904-909.
459 women with either microprolactinoma or idiopathic hyperprolactinemia were treated with Dostinex or bromocriptine in a double blind study for eight weeks.
Attainment of normal prolactin levels: 83% on Dostinex 59% on Bromocriptine
Attainment of ovulatory cycles or pregnancy: 72% on Dostinex 52% on Bromocriptine
Return of monthly periods: 93% on Dostinex 84% on Bromocriptine
Dostinex had significantly less side effects with shorter duration and less severity that bromocriptine. Only 3% of women on Dostinex quit treatment because of side effects versus 12% that stopped treatment due to intolerance on bromocriptine.
Biller BMK, et al. 1996. Treatment of prolactin secreting macroadenomas with once weekly agonist cabergoline. J Clin Endocrinol Metab 81: 2338-2343.
15 patients (8 women, 7 men) were treated with Dostinex, once weekly, for 48 weeks.
A 93.6% reduction in prolactin levels, with normal levels obtained in 73% of patients
5 patients who had previously been unable to achieve normal prolactin levels on other dopamine agonists, achieved normal prolactin levels on Dostinex
gonadal function was restored in all hypogonadal men
75% of premenopausal women with amenorrhea experienced return of gonadal function
11 of 15 patients experienced tumor shrinkage
minimal side effects – no patients discontinued Dostinex because of intolerance
Colao, A. et al. 1997. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11): 3574-3579.
23 patients with macroprolactinomas Results:
normalization of prolactin levels in 18 patients within 3-6 months at 0.5 mg/week
tumor volume reduction greater than 80% occurred in 61% of patients at the 12-24 month follow-up
the complete disappearance of the tumor occurred after 6 months in one patient and after 1 year of treatment in 5 patients
visual field defects were improved in 90% of patients who experienced them
In general, the data suggests that Dostinex is a better tolerated and a more effective dopamine agonist that bromocriptine in the treatment of prolactinomas. Dostinex effectively lowers prolactin levels and shrinks tumor size in a high percentage of cases, making it a good first option in the treatment of both micro- and macroprolactinomas.
10-29-2002, 05:15 PM #6
hey dumbass...how many times do i have to tell you i have our bromo on hand! lol see you tomorrow... miami was cool
Users Browsing this Thread
There are currently 1 users browsing this thread. (0 members and 1 guests)